VivoSeq
Rare Disease

Acromegaly

35

Pipeline Programs↗

9

Active Trials↗

16

Companies Involved↗

Acromegaly is a moderately active landscape with 35 programs across 16 companies. The most active players are Triastek (Shanghai) Limited, Ionis Pharmaceuticals, AstraZeneca. 4 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

22/100

Mech. Concentration

25/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Triastek (Shanghai) Limited

3 programs

Phase 1Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

3 programs

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 2C

Crinetics Pharmaceuticals Inc.

1 program

Phase 3R

RECORDATI GROUP

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

26 of 35 classified programs — the dominant modality here.

26%ALL OTHERSPeptide926%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 88% of 40 pipeline programs.

Analysis

Trial Status

69

clinical trials

Completed49 · 71%
Terminated6 · 9%
Recruiting4 · 6%
Unknown status3 · 4%
Active, not recruiting3 · 4%
Not yet recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

69 trials

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07037420·60 enrolled
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Recruiting·GGinkgo Leaf Center for Rare Disorders·N/A·NCT03158090·1,965 enrolled
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
Recruiting·CCamurus AB·N/A·NCT07583563·200 enrolled
A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs
Recruiting·DDebiopharm International SA·Phase 3·NCT06930625·119 enrolled
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Active, not recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT04837040·58 enrolled
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Active, not recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT05192382·111 enrolled
An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)
Active, not recruiting·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT04261712·43 enrolled
A Phase 1, Single-center, Open-Label, Randomized, Three-Period, Six-Sequence, Single-Dose, Crossover Study in Healthy Participants Under Fasted or Fed Condition to Compare the Relative Bioavailability of Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®) and to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25
Not yet recruiting·TTriastek (Shanghai) Limited·Phase 1·NCT07663318·18 enrolled
Determination of the Appropriate Intubation Method in Patients With Acromegaly: Comparison of Direct Laryngoscopy and Video Laryngoscopy
Not yet recruiting·MMuzaffer GENCER·N/A·NCT07659912·40 enrolled
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 2·NCT03967249·39 enrolled
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Completed·Novartis logoNovartis·Phase 3·NCT02354508·123 enrolled
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Completed·Ipsen logoIpsen·Phase 4·NCT00216398·8 enrolled
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
Completed·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT03789656·47 enrolled
Clomiphene Citrate for Treatment of Acromegaly
Completed·FFelipe Henning Gaia Duarte·Phase 2·NCT02274311·16 enrolled
Open Label Study of Octreotide Implant in Patients With Acromegaly
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT00913055·34 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)